Images List Premium Download Classic

Vaccine

Vaccine-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Anti-lag3 antibodies and antigen-binding fragments
Merck Sharp & Dohme Corp.
October 12, 2017 - N°20170290914

The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey lag3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e. G., including anti-pd1 antibodies) are included ...
Pyrazolopyrimidine compounds
Merck Sharp & Dohme Corp.
October 12, 2017 - N°20170290910

Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be ...
Biochemically stabilized hiv-1 env trimer vaccine
Children's Medical Center Corporation
October 12, 2017 - N°20170290907

Stabilized trimers of a clade a strain and a clade c strain of hiv-1 are provided. Broadly neutralizing antisera against hiv-1, methods of making broadly neutralizing antisera against hiv-1, broadly neutralizing vaccines against hiv-1, as well as methods of treating subjects infected with hiv, preventing hiv infection, and inhibiting hiv-mediated activities are also provided.
Vaccine Patent Pack
Download + patent application PDFs
Vaccine Patent Applications
Download + Vaccine-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Vaccine-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Multicomponent or monocomponent vaccine to be used against chagas disease, pharmaceutical compositions containing them, procedure ...
The United States Of America, As Represented By The Secretary Department Of Health And Human Ser..
October 12, 2017 - N°20170290896

A monocomponent vaccine effective to moderate the clinical consequences of chages disease, capable of stimulating an immune response against the trans-sialidase virulence factor of the trypanosoma cruzi parasite. The vaccine active ingredient is an immunogenic component with a polynucleotide encoding one or more polypeptide(s) which includes a c-terminal region composed of at least two repetitive units of amino acids, ...
Compositions and methods for dengue virus chimeric constructs in vaccines
The Government Of The United States Of America As Represented By The Secretary Of The Department
October 12, 2017 - N°20170290884

Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (den-1) virus, dengue-2 (den-2) virus, dengue-3 (den-3) or dengue-4 (...
Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
Academia Sinica
October 05, 2017 - N°20170283878

The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid ssea-3/ssea-4/globoh in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4galt; beta-4galnact-i; or beta-3galt-v ...
Vaccine Patent Pack
Download + patent application PDFs
Vaccine Patent Applications
Download + Vaccine-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Vaccine-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Triterpene saponins, methods of synthesis and uses thereof
Memorial Sloan-kettering Institute For Cancer Research
October 05, 2017 - N°20170283450

The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. Qs-7 is a potent immuno-adjuvant that is significantly less toxic than qs-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of qs-7. A novel semi-synthetic method is provided ...
Equine disease model for herpesvirus neurologic disease and uses thereof
University Of Kentucky Research Foundation
October 05, 2017 - N°20170281751

The present invention relates to an in vivo equine disease model for equine herpesvirus-1 neurological disease comprising a horse having a low pre-exposure level of herpesvirus-specific ctl precursors and/or is approximately 20 years of age or older wherein the horse is experimentally infected with a neuropathogenic strain of equine herpesvirus or a mutant thereof. The invention includes a method of ...
Therapeutic hpv16 vaccines
Janssen Vaccines & Prevention B.v.
October 05, 2017 - N°20170281747

Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against hpv16.
Interaction of moraxella catarrhalis with epithellal cells, extracellular matrix proteins and the complement system
Arne Forsgren Ab
October 05, 2017 - N°20170281746

The present disclosure relates to surface proteins of moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting with fibronectin, laminin and the complement system.
Methods for constructing antibiotic resistance free vaccines
The Trustees Of The University Of Pennsylvania
October 05, 2017 - N°20170281691

The present invention provides listeria vaccine strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.
Recombinant chicken interleukin-1 beta protein for producing antibody early and retaining for a longer period ...
National Tsing Hua University
September 28, 2017 - N°20170275349

The present invention provides a recombinant chicken interleukin-1β protein for producing antibody early and retaining for a longer period of time, which has a sequence of seq id no:2 or seq id no:3. The recombinant chicken interleukin-1β protein is created by using point mutation in a genetic engineering method; it can significantly improve the original vaccine ...
Cytotoxic t lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection
Emergex Vaccines Holdings Limited
September 28, 2017 - N°20170275338

Dengue fever (df) and dengue hemorrhagic fever (dhr) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive t cell responses. ...
Vaccine Patent Pack
Download + patent application PDFs
Vaccine Patent Applications
Download + Vaccine-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Vaccine-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Vaccines for hsv-2
Immune Design Corp.
September 28, 2017 - N°20170274066

Compositions of recombinant hsv-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e. G., a capsid or tegument protein. The vaccine is for use in either hsv-2 seropositive or seronegative subjects.
Attenuated bovine coronavirus and related vaccines
Intervet Inc.
September 28, 2017 - N°20170274065

The present invention discloses novel attenuated bovine coronavirus isolates, compositions comprising these isolate, and methods of using such compositions in vaccines, including in live vaccines. The present invention further discloses the administration of such vaccines, including the intranasal administration of such vaccines, to aid in the prevention of respiratory disease caused by bovine coronavirus.
Modified bat influenza viruses and their uses
Kansas State University Research Foundation
September 28, 2017 - N°20170274064

Vaccine compositions useful for vaccination against a target influenza strain, and method and kits for using the same. The vaccines comprise a live attenuated influenza virus that is synthetically constructed based upon a backbone platform derived from a bat influenza strain, and heterologous surface proteins ha and na derived from the target influenza strain. The live attenuated virus is non-reassortant ...
Purified plasmodium and vaccine compositions
Sanaria Inc.
September 28, 2017 - N°20170274061

Disclosed are substantially purified plasmodium sporozoites and preparations of plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified plasmodium sporozoites are likewise provided. Methods of purifying preparations of plasmodium sporozoites are also provided.
Mobile pharmacy
Sanaria Inc.
September 21, 2017 - N°20170270275

A mobile pharmacy may provide services for a group of people who have similar medical considerations. For example, a group intending to visit another country may require certain vaccinations or medications. For another example, a group of people working at a common employer may have medical requirements related to a chronic disease. A mobile pharmacy may allow a pharmacist to ...
Ompa in vaccine compositions and as diagnostic targets
Virginia Commonwealth University
September 21, 2017 - N°20170269080

Anaplasma marginale surface protein ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to ompa proteins can be used ...
Anti-lag3 antibodies and antigen-binding fragments
Merck Sharp & Dohme Corp.
September 21, 2017 - N°20170267759

The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey lags as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e. G., including anti-pd1 antibodies) are included ...
Glypican-3-specific t-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
Technische Universität München
September 21, 2017 - N°20170267737

The present invention relates to glypican-3-specific t-cell receptors. The present invention further relates to soluble tcr constructs, chimeric tcrs, bi-specific antibodies, nucleic acids, expression constructs and cells comprising said tcrs or tcr constructs. The present invention further relates to the use of the tcr or the soluble tcr constructs or chimeric tcrs or bi-specific antibodies as a medicament, preferably ...
Loading